Evidence map›Paper›PMID 41684594›Full record

ArticleFrontiers in oncology2026

Ceritinib efficacy in SMARCA4-deficient NSCLC harboring novel CTNND2 ALK/EML4-ALK fusion: case report.

Zhigang Fu, Gengda Huang, Jian Xie, Li Luo, Qinqin Ren, Hong He, Yuan Wang, Jiexia Zhang

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhigang Fu *The Seventh Affiliated Hospital of Southern Medical University, Foshan, China.
Gengda Huang *Guangzhou Institute of Respiratory Disease, State Key Laboratory of Respiratory Disease, Department of Respiration, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Jian XieDepartment of Radiation Oncology, The First Affiliated Hospital,Sun Yat-sen University, Guangzhou, China.
Li LuoDepartment of Pulmonary and Critial Care Medicine of Jiangbei Guangzhou Medical University, Guangzhou, Guangdong, China.
Qinqin RenDepartment of Pulmonary and Critial Care Medicine of Jiangbei Campus,The First Affiliated Hospital of Army Medical University, Chongqing, China.
Hong HeGuangzhou Institute of Respiratory Disease, State Key Laboratory of Respiratory Disease, Department of Respiration, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yuan WangGuangzhou Institute of Respiratory Disease, State Key Laboratory of Respiratory Disease, Department of Respiration, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Jiexia ZhangGuangzhou Institute of Respiratory Disease, State Key Laboratory of Respiratory Disease, Department of Respiration, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC) is an aggressive malignancy with poor prognosis, rarely harboring EGFR, ALK, or ROS1 alterations. We report an advanced SMARCA4-dNSCLC case with brain metastasis exhibiting a novel CTNND2-ALK/EML4-ALK double-fusion. Following platinum-based chemotherapy and brain radiotherapy, next-generation sequencing identified the dual fusions (abundances: 2.6% and 5.2%), confirmed by ALK protein expression. The patient subsequently received ceritinib (750 mg/day). After 3 months, targeted lesions regressed significantly, and progression-free survival exceeded 24 months with ongoing response. This demonstrates efficacy of the ALK inhibitor ceritinib in ALK-rearranged SMARCA4-dNSCLC and underscores the clinical value of genomic-guided therapy.

Indexed as

ALK double-fusionceritinibCTNND2-ALKNSCLCSMARCA4-dNSCLC

Identifiers

PMID41684594
PMCPMC12890615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.